Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17475871rdf:typepubmed:Citationlld:pubmed
pubmed-article:17475871lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:17475871lifeskim:mentionsumls-concept:C0030498lld:lifeskim
pubmed-article:17475871lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:17475871lifeskim:mentionsumls-concept:C0024534lld:lifeskim
pubmed-article:17475871lifeskim:mentionsumls-concept:C1415900lld:lifeskim
pubmed-article:17475871lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:17475871lifeskim:mentionsumls-concept:C2828008lld:lifeskim
pubmed-article:17475871pubmed:issue10lld:pubmed
pubmed-article:17475871pubmed:dateCreated2007-5-3lld:pubmed
pubmed-article:17475871pubmed:abstractTextMost C57BL/6 mice infected i.p. with Plasmodium berghei ANKA (PbA) die between 7 and 14 days with neurologic signs, and the remainder die later (>15 days) with severe anemia. Daily i.p. injections of a recombinant human IFN-alpha (active on mouse cells) prevented death by cerebral malaria (87% deaths in the control mice vs 6% in IFN-alpha-treated mice). The mechanisms of this IFN-alpha protective effect were multiple. IFN-alpha-treated, PbA-infected mice showed 1) a marked decrease in the number of PbA parasites in the blood mediated by IFN-gamma, 2) less sequestered parasites in cerebral vessels, 3) reduced up-regulation of ICAM-1 expression in brain endothelial cells, 4) milder rise of blood levels of TNF, 5) increased levels of IFN-gamma in the blood resulting from an increased production by splenic CD8+ T cells, and 6) fewer leukocytes (especially CD8+ T cells) sequestered in cerebral vessels. On the other hand, IFN-alpha treatment did not affect the marked anemia observed in PbA-infected mice. Survival time in IFN-alpha-treated mice was further increased by performing three blood transfusions over consecutive days.lld:pubmed
pubmed-article:17475871pubmed:languageenglld:pubmed
pubmed-article:17475871pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17475871pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17475871pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17475871pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17475871pubmed:statusMEDLINElld:pubmed
pubmed-article:17475871pubmed:monthMaylld:pubmed
pubmed-article:17475871pubmed:issn0022-1767lld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:SnounouGeorge...lld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:GresserIonIlld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:MazierDominiq...lld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:RéniaLaurentLlld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:BelnoueElodie...lld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:VigárioAna...lld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:KayibandaMich...lld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:DescheminJean...lld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:GrünerAnne...lld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:MauduitMarjor...lld:pubmed
pubmed-article:17475871pubmed:authorpubmed-author:MarussigMyria...lld:pubmed
pubmed-article:17475871pubmed:issnTypePrintlld:pubmed
pubmed-article:17475871pubmed:day15lld:pubmed
pubmed-article:17475871pubmed:volume178lld:pubmed
pubmed-article:17475871pubmed:ownerNLMlld:pubmed
pubmed-article:17475871pubmed:authorsCompleteYlld:pubmed
pubmed-article:17475871pubmed:pagination6416-25lld:pubmed
pubmed-article:17475871pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:meshHeadingpubmed-meshheading:17475871...lld:pubmed
pubmed-article:17475871pubmed:year2007lld:pubmed
pubmed-article:17475871pubmed:articleTitleRecombinant human IFN-alpha inhibits cerebral malaria and reduces parasite burden in mice.lld:pubmed
pubmed-article:17475871pubmed:affiliationInstitut Cochin, Département d'Immunologie, Paris, France.lld:pubmed
pubmed-article:17475871pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17475871pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17475871lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17475871lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17475871lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17475871lld:pubmed